Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle

Metabolomics

Volumn 8, Issue 3, 2012, Pages 454-464

  Zanuy, Miriam ^a   Ramos Montoya, Antonio ^a,d   Villacañas, Oscar ^a,e   Canela, Nuria ^b   Miranda, Anibal ^a   Aguilar, Esther ^a   Agell, Neus ^b   Bachs, Oriol ^b   Rubio Martinez, Jaime ^a   Pujol, Maria Dolors ^a   Lee, Wai Nang P ^c   Marin, Silvia ^a   Cascante, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^e Intelligent Pharma SL   (Spain)

Author keywords

CDK inhibitor; Cyclin dependent kinases; Pentose phosphate pathway; Phase plane analysis; Tracer based metabolomics

Indexed keywords

CALCEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; COLON ADENOCARCINOMA; CONTROLLED STUDY; GEL ELECTROPHORESIS; GLUCOSE OXIDATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOLECULAR MODEL; PENTOSE PHOSPHATE CYCLE; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH;

EID: 84861221308     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-011-0328-x     Document Type: Article

References (45)

1. Boros, L. G., Puigjaner, J., Cascante, M., Lee, W. N., Brandes, J. L., Bassilian, S., et al. (1997). Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Research, 57, 4242-4248.
2. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
3. Comin-Anduix, B., Boros, L. G., Marin, S., Boren, J., Callol-Massot, C., Centelles, J. J., et al. (2002). Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells. Journal of Biological Chemistry, 277, 46408-46414.
4. Edwards, J. S., Ramakrishna, R., & Palsson, B. O. (2002). Characterizing the metabolic phenotype: a phenotype phase plane analysis. Biotechnology and Bioengineering, 77, 27-36.
5. Frangioni, J. V., & Neel, B. G. (1993). Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Analytical Biochemistry, 210, 179-187.
6. Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., et al. (2004). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics, 3, 1427-1438.
7. Graf, F., Koehler, L., Kniess, T., Wuest, F., Mosch, B., & Pietzsch, J. (2009). Cell cycle regulating kinase Cdk4 as a potential target for tumor cell treatment and tumor imaging. Journal of Oncology, 2009, 106378.
8. Hall, M., & Peters, G. (1996). Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Advances in Cancer Research, 68, 67-108.
9. Harlow, E. & Lane, D. (Eds.). (1988). Antibodies: a laboratory manual (p. 469). New York: Cold Spring Harbor Laboratory Press.
10. Jonsson, B., Liminga, G., Csoka, K., Fridborg, H., Dhar, S., Nygren, P., et al. (1996). Cytotoxic activity of calcein acetoxymethyl ester (calcein/AM) on primary cultures of human haematological and solid tumours. European Journal of Cancer, 32A, 883-887.
11. Kuo, W., Lin, J., & Tang, T. K. (2000). Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. International Journal of Cancer, 85, 857-864.
12. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
13. Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006). Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell, 9, 13-22.
14. Lee, W. N. P. (2006). Characterizing phenotype with tracer based metabolomics. Metabolomics, 2, 31-39.
15. Lee, W. N., Boros, L. G., Puigjaner, J., Bassilian, S., Lim, S., & Cascante, M. (1998). Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1, 2-13C2]glucose. American Journal of Physiology, 274, E843-E851.
16. Lee, W. N., Byerley, L. O., Bergner, E. A., & Edmond, J. (1991). Mass isotopomer analysis: theoretical and practical considerations. Biological Mass Spectrometry, 20, 451-458.
17. Liminga, G., Jonsson, B., Nygren, P., & Larsson, R. (1999). On the mechanism underlying calcein-induced cytotoxicity. European Journal of Pharmacology, 383, 321-329.
18. Liminga, G., Martinsson, P., Jonsson, B., Nygren, P., & Larsson, R. (2000). Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB. Biochemical Pharmacology, 60, 1751-1759.
19. Liminga, G., Nygren, P., Dhar, S., Nilsson, K., & Larsson, R. (1995). Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: drug delivery by intracellular trapping. Anticancer Drugs, 6, 578-585.
20. Lundberg, A. S., & Weinberg, R. A. (1998). Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Molecular and Cellular Biology, 18, 753-761.
21. Mahale, S., Aubry, C., Jenkins, P. R., Marechal, J. D., Sutcliffe, M. J., & Chaudhuri, B. (2006). Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin. Bioorganic Chemistry, 34(5), 287-297.
22. Malumbres, M., & Barbacid, M. (2001). To cycle or not to cycle: a critical decision in cancer. Nature Reviews Cancer, 1, 222-231.
23. Malumbres, M., & Barbacid, M. (2006). Is cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell, 9, 2-4.
24. Malumbres, M., Sotillo, R., Santamaria, D., Galan, J., Cerezo, A., Ortega, S., et al. (2004). Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell, 118, 493-504.
25. Marzec, M., Kasprzycka, M., Lai, R., Gladden, A. B., Wlodarski, P., Tomczak, E., et al. (2006). Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood, 108, 1744-1750.
26. Matito, C., Mastorakou, F., Centelles, J. J., Torres, J. L., & Cascante, M. (2003). Antiproliferative effect of antioxidant polyphenols from grape in murine Hepa-1c1c7. European Journal of Nutrition, 42, 43-49.
27. McInnes, C. (2008). Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discovery Today, 13, 875-881.
28. Menu, E., Garcia, J., Huang, X., Di Liberto, M., Toogood, P. L., Chen, I., et al. (2008). A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Research, 68, 5519-5523.
29. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
30. Myohanen, S. K., Baylin, S. B., & Herman, J. G. (1998). Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Research, 58, 591-593.
31. Poulsen, H. S., & Frederiksen, P. (1981). Glucose-6-phosphate dehydrogenase activity in human breast cancer. Lack of association with oestrogen receptor content. Acta Pathol Microbiol Scand [A], 89, 263-270.
32. Ramos-Montoya, A., Lee, W.-N. P., Bassilian, S., Lim, S., Trebukhina, R. V., Kazhyna, M. V., et al. (2006). Pentose phosphate cycle oxidative and non-oxidative balance: a new vulnerable target for overcoming drug resistance in cancer. International Journal of Cancer, 119, 2733-2741.
33. Rubio-Martinez, J., Pinto, M., Tomas M. S., Perez, J. J. (2005). Dock_Dyn: a program for fast molecular docking using molecular dynamics information. University of Barcelona and Technical University of Catalonia.
34. Santamaria, D., & Ortega, S. (2006). Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Frontiers in Bioscience, 11, 1164-1188.
35. Shapiro, G. I. (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology, 24, 1770-1783.
36. Sherr, C. J. (1996). Cancer cell cycles. Science, 274, 1672-1677.
37. Sherr, C. J., & Roberts, J. M. (2004). Living with or without cyclins and cyclin-dependent kinases. Genes and Development, 18, 2699-2711.
38. Smith, D. B., & Johnson, K. S. (1988). Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene, 67, 31-40.
39. Villacanas, O., Perez, J. J., & Rubio-Martinez, J. (2002). Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 20, 347-358.
40. Villacanas, O., & Rubio-Martinez, J. (2006). Reducing CDK4/6-p16(INK4a) interface. Computational alanine scanning of a peptide bound to CDK6 protein. Proteins, 63, 797-810.
41. Vizan, P., Alcarraz-Vizán, G., Diaz-Moralli, S., Rodriguez-Prados, J. C., Zanuy, M., Centelles, J. J., et al. (2007). Quantification of intracellular phosphorylated carbohydrates in HT29 human colon adenocarcinoma cell line using liquid chromatography-electrospray ionization tandem mass spectrometry. Analytical Chemistry, 79(13), 5000-5005.
42. Vizan, P., Alcarraz-Vizan, G., Diaz-Moralli, S., Solovjeva, O. N., Frederiks, W. M., & Cascante, M. (2009). Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. International Journal of Cancer, 124, 2789-2796.
43. Vizán, P., Mazurek, S., & Cascante, M. (2008). Robust metabolic adaptation underlying tumor progression. Metabolomics, 4, 1-12.
44. Warburg, O. (1956). Origin of cancer cells. Oncologia, 9, 75-83.
45. Yu, Q., Sicinska, E., Geng, Y., Ahnstrom, M., Zagozdzon, A., Kong, Y., et al. (2006). Requirement for CDK4 kinase function in breast cancer. Cancer Cell, 9, 23-32.